论文部分内容阅读
随着医学科学的飞速发展,各领域新药开发已达到相当水平。但人工器官的研究尚处新材料、新技术开发阶段。鉴于患者非免疫顺应药物的疗效减弱,副作用增加;既往药品剂型有效浓度又介于无效和副作用阈值浓度之间;半衰期较短的药物必须反复应用等原因,为尽可能提高现有药品的疗效,减少副作用,将医药品本身的研究和包括剂型改革及应用手段的研究巧妙地结合(其中有药物的化学修饰、前体化、剂型、给药方法、联合应用等),以达到治疗目的。因而产生了药物控制递释方式(durg delivery system,DDS)的新概念。DDS 的主要目的是对进入人体内的药物要到达的部位——标的(即靶,包括器官、组织、细胞、病原
With the rapid development of medical science, the development of new drugs in various fields has reached a considerable level. However, the study of artificial organs is still at a stage of development of new materials and new technologies. In view of the weakened curative effect of non-immunocompromised patients, the side effects are increased; the effective concentration of the prior drug formulations is between the ineffective and the threshold concentration of side effects; the drugs with shorter half-life must be repeatedly applied and so on. In order to improve the curative effect of the existing drugs as much as possible, Reduce the side effects, and combine the research of pharmaceutical products itself with the research including formulation reform and application means (including chemical modification of drugs, priming, dosage form, administration method and combination application) to achieve the therapeutic goal. The result is a new concept of durg delivery system (DDS). The main purpose of DDS is to enter the body of the drug to reach the site - the target (ie target, including organs, tissues, cells, pathogens